Grand Pharmaceutical Group Limited announced that the Investigational New Drug (IND) application in China of the Group's global innovative ophthalmic drug GPN00884 used to delay the progression of myopia in children, was officially approved by the National Medical Products Administration of the People's Republic of China (NMPA) recently. This study is a randomized, double-blind, placebo-controlled, and dose-escalating Phase I clinical trial to evaluate the safety, tolerability and pharmacokinetic features of GPN00884 eye drops in healthy subjects after single and multiple dosing. GPN00884 eye drops are an innovative drug with a new mechanism used to delay the progression of myopia in children.

Compared with low-concentration atropine eye drops, GPN00884 eye drops have no mydriasis effect, no adverse reactions such as photophobia and decreased accommodation, and the dosing period is not limited, which can improve patient compliance. At present, there is still a lack of drugs with clear efficacy and safety in terms of delaying the progression of myopia in children in China, indicating an unmet clinical need in the field of this disease. GPN00884 eye drops are expected to provide doctors and patients with a new clinical treatment solution for delaying the progression of myopia in children.